




RealRate

PHARMACEUTICAL 2018

Spero Therapeutics Inc.
Rank 149 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

The relative strengths and weaknesses of Spero Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Spero Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 304% points. The greatest weakness of Spero Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is -134%, being 143% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	92,059
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,157
Liabilities, Non-Current	0
Other Assets	256
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	365
Other Net Income	3,823
Property and Equipment	1,164
Research and Development	32,869
Revenues	0
Selling, General and Administrative Expense	10,840

Output Variable	Value in 1000 USD
Assets	93,479
Liabilities	8,522
Expenses	43,709
Stockholders Equity	84,957
Net Income	-39,886
Comprehensive Net Income	-39,886
Economic Capital Ratio	-134%